---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-164004"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2024-06-20T23:59:59+00:00"
generated_at: "2026-06-01T03:37:57.269191+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma increases Evrysdi royalty stake to 90.5% for $242M from PTC option exercise

## Summary
- PTC exercised option to sell half its retained Evrysdi royalty to Royalty Pharma for ~$242M upfront.
- Royalty Pharma's Evrysdi royalty ownership increases from 81% to 90.5% (before cap).
- Evrysdi (SMA drug) generated 2023 sales of ~CHF 1.4B ($1.6B), up 39% YoY at CER.
- Total upfront investment in Evrysdi royalties now $1.9B; effective royalty rate 7.2%-14.5%.
- PTC retains option to sell remaining 9.5% royalty for $250M less royalties received until Dec 2025.

## SEC filing metadata
- accession: 0001193125-24-164004
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2024-06-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312524164004/0001193125-24-164004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312524164004/d724682d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-164004
- JSON: https://secwatch.observer/filing/0001193125-24-164004.json
- Plain text: https://secwatch.observer/filing/0001193125-24-164004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.